Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Alisertib,Anastrozole
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Puma Biotechnology Allowed to Proceed Under IND for Alisertib in Metastatic Breast Cancer
Details : MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.
Brand Name : MLN8237
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2024
Lead Product(s) : Alisertib,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Alisertib,Anastrozole
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.
Brand Name : MLN8237
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2023
Lead Product(s) : Alisertib,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Abemaciclib,Anastrozole
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Verzenio (abemaciclib) is a small molecule CDK4/CD6 inhibitor which is under phase 3 clinical development in combination with anastrozole for the treatment of post-menopausal patients with HR+/HER2-, advanced or metastatic breast cancer.
Brand Name : Verzenio
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Lead Product(s) : Abemaciclib,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ribociclib,Anastrozole
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Kisqali® (ribociclib) is the only USFDA approved category 1 preferred CDK4/6 inhibitor for first-line treatment of patients with HR+/HER2- MBC when combined with an AI.
Brand Name : Kisqali
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 27, 2023
Lead Product(s) : Ribociclib,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Onapristone,Anastrozole
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ONA-XR (onapristone) is a selective progesterone receptor (PR) antagonist designed to block both ligand dependent and ligand-independent activity of PR which downregulates cancer stem cellmobilization, and blocking immune evasion.
Brand Name : ONA-XR
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 06, 2023
Lead Product(s) : Onapristone,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ribociclib,Anastrozole,Goserelin Acetate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Kisqali (ribociclib) is the only CDK4/6 inhibitor with proven overall survival benefit across all three pivotal Phase III advanced breast cancer trials and is recognized as the only CDK4/6i with overall survival benefit in first-line HR+/HER2- advanced b...
Brand Name : Kisqali
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 06, 2022
Lead Product(s) : Ribociclib,Anastrozole,Goserelin Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Testosterone Undecanoate,Anastrozole
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CLAR-121 is combination of testosterone undecanoate (natural ligand for the androgen receptor and anastrozole delivered by a subcutaneous implant for treatment of AR-mediated inflammatory breast disease that predominantly affects women.
Brand Name : CLAR-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 10, 2022
Lead Product(s) : Testosterone Undecanoate,Anastrozole
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Onapristone,Anastrozole
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Context Therapeutics Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting
Details : Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR (onapristone extended release) demonstrates monotherapy clinical activity in advanced granulosa cell tumor of the ovary.
Brand Name : ONA-XR
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 05, 2022
Lead Product(s) : Onapristone,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Testosterone,Anastrozole
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Clarus Therapeutics
Deal Size : $11.2 million
Deal Type : Licensing Agreement
Clarus Therapeutics and HavaH Therapeutics Announce Licensing Agreement
Details : CLAR-121 is a proprietary combination of testosterone (T) (natural ligand for the androgen receptor; AR) and anastrozole (inhibitor of T conversion to estradiol) delivered by a subcutaneous implant for treatment of AR-mediated breast disease that predomi...
Brand Name : CLAR-121
Molecule Type : Small molecule
Upfront Cash : $0.5 million
May 25, 2021
Lead Product(s) : Testosterone,Anastrozole
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Clarus Therapeutics
Deal Size : $11.2 million
Deal Type : Licensing Agreement
Lead Product(s) : Anastrozole
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Juvise Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Juvise Pharmaceuticals Successfully Syndicated Its EUR 213 Million Financing in Less than One Month
Details : Arimidex® (anastrozole) and Casodex® (bicalutamide) are hormone treatments for breast and prostate cancer. The two products are recognized as pillar in those cancer treatments and essential for both patients and physicians.
Brand Name : Arimidex
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 04, 2020
Lead Product(s) : Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Juvise Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?